… thyroid cancer (PTC), and it can be associated with an unfavorable prognosis of PTC (5–8). …
of the BRAF V600E mutation in thyroid cancer, the clinical utility of RAS mutations has not …

… molecular markers of thyroid cancer have been identified that offer diagnostic, prognostic,
and … might be of value in guiding individualized management of patients with thyroid nodules. …

… The implications of our study that higher serum TSH is associated with worse thyroid cancer
prognosis may have clinical utility. Our findings suggest that those with elevated TSH at …

… The genes, coding the signaling cascade proteins (RET, RAS, BRAF, PI3K, PTEN, AKT),
are mutated or aberrantly expressed in thyroid cancer derived from follicular thyroid cell. …

… Although cancer outcome results from the interplay between genetics and environment, …
thyroid cancer (DTC). Nevertheless, role of molecular characterisation in the prognostic setting …

… These novel molecular-based management strategies for thyroid nodules and thyroid cancer
are … Papillary thyroid cancer and follicular thyroid cancer are differentiated thyroid cancers, …

… utilities obtained from clinicians caring for thyroid cancer … Rather than obtaining values for
these 2 utilities from a … each patient's preferences regarding thyroid hormone dependency and …

… In conclusion, genetic mutations should be considered to be poor prognostic markers in
thyroid cancer; such knowledge might improve the management of individual patients. However, …

… clinical cancers. Therefore, there is an urgent need for new tools able to predict which thyroid
cancers will remain silent, and which thyroid cancers … of any prognostic utility for BRAF (58). …

… papillary thyroid cancer and Hashimoto's thyroiditis that may have a favorable prognostic …
and may be a more specific thyroid tumor marker than thyroid peroxidase antibodies. TgAb …